Real-World data shows mepolizumab may keep rare vasculitis in check Long-Term
NCT ID NCT07591753
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by reviewing medical records. The goal is to understand if this dose helps patients stay well and reduce steroid use without unexpected side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mepolizumab (a biologic drug given as a shot every 4 weeks)
What this could lead to
If successful, this could confirm that mepolizumab 300mg/month is a safe and effective long-term treatment to control EGPA and reduce steroid use.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It also looks back at existing data, which can be less reliable than a prospective study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) (EGPA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florence
Florence, Florence, 50134, Italy